Oncotelic Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $11.0M
- Price
- $0.024
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 327.2K
About
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Quick stats
Shares outstanding457.5M
Computed float311.9M
Float / shares68.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000908259
Websitehttps://www.oncotelic.com
AI Summary
AI-generated1/31
minorneutralproduct launch
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
Oncotelic Therapeutics announced that its PDAOAI AI drug discovery platform is opening a free collaboration initiative called BIO REBOOT, inviting scientists, AI developers and biotech founders to submit research questions and drug discovery ideas.
Selected projects may be considered for startup funding and Oncotelic development support, subject to scientific review and available resources. The announcement accompanies keynote presentations by executives at the Drug Discovery 2026 conference, including a hepatocellular carcinoma case study where PDAOAI identified a candidate four-gene mTOR signature from 4.4 million abstracts.
PDAOAI is built on an index of 29 million PubMed abstracts and is a visibility play for the company's AI platform rather than a clinical or financial catalyst; funding terms are non-committal.
Red flags
- funding and platform access are 'subject to scientific review, available resources and agreed terms' -- no committed capital
- promotional conference announcement with no clinical, regulatory, or financial substance